Back

Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Antidiabetic drugs for treatment of cardiovascular disease Heart Failure ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Frederick Sinha

University Hospital Regensburg, Regensburg (Germany)

7 More presentations in this session

Presentation thumbnail
Human epicardial adipose tissue-derived factors promote atrial endothelial dysfunction: role of pro-inflammatory cytokines and AT1R/NADPH oxidases/SGLT2 pro-oxidant pathway
Doctor W. Fakih (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Takotsubo syndrome induced oxidative stress and endothelial dysfunction in left ventricle of rat model: association with NADPH oxidases/SGLT2 pro- oxidant pathway
Miss T. Tatarcheh (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Investigating the effects of empagliflozin on myocardial metabolic and lipid profile in healthy and metabolic syndrome murine models following acute myocardial infarction
Professor I. Andreadou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Semaglutide improves contractile function in isolated human atrium
Doctor P. Hegner (Regensburg, DE)
Abstract Slides Video
Presentation thumbnail
Semaglutide modulates pro-inflammatory neutrophil phenotype induced by supraphysiological levels of the adipokine FABP4 in patients with cardiovascular disease.
Doctor S. Eiras (Santiago de Compostela, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Antidiabetic drugs for treatment of cardiovascular disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Empagliflozin preserves hemodynamics and left ventricular function in nephrectomized rats after ischemia-reperfusion injury: a potential direct cardioprotective effect of SGLT2 inhibitor
thumbnail
Congress Presentation
Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial
thumbnail
Congress Presentation
Mid-term renal impact of SGLT2 inhibitors in heart failure: a systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources